Objective Hepatitis B virus (HBV) can integrate into the chromosomes of infected hepatocytes, contributing to the production of hepatitis B surface antigen (HBsAg ... encompassed normal hepatocytes, T ...

Vir Biotechnology’s sidelined hepatitis B candidate, designed to serve as a “functional cure,” has failed to achieve the ...

Vir Bio (VIR) reveals 24-week post-end-of-treatment data from a mid-stage trial for its Hep B therapy developed with Xencor ...

For patients with chronic viral hepatitis, clinicians instinctively rely on liver enzyme measurements to estimate disease activity and assess need for liver biopsy or antiviral treatment.

Discover a recent study presented at EASL 2025 that explored the impact of opt-out testing for blood-borne viruses in ...

Assays for hepatitis B surface antigen (HBsAg) are the most frequently used tests to detect HBV infection. Vaccination for HBV can produce transiently detectable levels of HBsAg in patients.

Interim results from the phase 2b B-Clear showed that bepirovirsen reduced levels of hepatitis B surface antigen (HBsAg) and HBV DNA after 24 weeks' treatment to below the lower limit of detection ...

bepirovirsen at a dose of 300 mg per week over 24 weeks resulted in sustained hepatitis B surface antigen (HBsAg) and HBV DNA loss to below the limits of detection in 9% to 10% of participants ...

would be considered long-tail data points that consequently lie squarely outside of the three-standard-deviation range. Bell Curve vs. Non-Normal Distributions The normal probability distribution ...

The duration of hepatitis B surface antigen (HBsAg) exposure (indicated by the patient’s age), rather than the quantity of HBsAg, was associated with the level of anti-HBV immune response, in ...